Pioneering Pharmaceutical Growth from India to the World
Empowering the Pharmaceutical Industry with World-Class Infrastructure and Opportunities
Semicon City (Semicon City) is positioned to be India’s leading pharmaceutical and life sciences hub. With seamless connectivity through the Delhi-Mumbai Industrial Corridor, state-of-the-art facilities, and access to India’s deepest port, Semicon City offers unparalleled opportunities for investors in pharmaceuticals. From generic drugs and active pharmaceutical ingredients (APIs) to vaccines and biosimilars, Semicon City is your gateway to the world’s fastest-growing pharmaceutical market.
Why India’s Pharmaceutical Industry is a Global Leader
- Volume Leader: Ranked 3rd globally by volume, with a market size of USD 50 billion in FY 2022-23.
- Vaccine Giant: Largest vaccine manufacturer, supplying 60% of global vaccine demand.
- Generic Powerhouse: Accounts for 20% of the global supply of generic drugs.
- Growth Momentum: Projected to grow to USD 130 billion by 2030, driven by rising demand and innovation.
Growth Drivers for Pharmaceutical Investors in Semicon City
- Rising Healthcare Coverage: Initiatives like Ayushman Bharat (PMJAY) cover 500 million beneficiaries, increasing access to healthcare.
- Expanding Middle Class: Rising income levels and insurance coverage are driving pharmaceutical demand.
- Chronic Disease Growth: With an aging population and lifestyle changes, India’s patient pool is projected to grow by 20% in the next decade.
- Robust R&D Ecosystem: Home to 7 NIPERs and 500+ contract research labs, India is a hub for innovation and clinical trials.
- Skilled Workforce: Over 2.24 million STEM students ensure a steady talent pipeline.
- Global Standards: India hosts the most US FDA-approved plants outside the US, ensuring high compliance standards.
Government Policies Supporting Pharmaceutical Growth
- 100% FDI: Automatic route for greenfield projects and government route for brownfield investments.
- Production Linked Incentive (PLI) Scheme: Incentives to boost manufacturing of APIs, bulk drugs, and biosimilars.
- PRIP Scheme: Establishes Centers of Excellence at NIPERs, fostering innovation and R&D.
- Clinical Trial Reforms: Fast-track drug approvals and waiver of clinical trials for drugs approved in regulated markets.
Semicon City’s Dedicated Services for Pharmaceutical Investors
Investor Targeting
Tailored strategies to attract global pharmaceutical leaders to Semicon City.
Investor Aftercare
Comprehensive post-investment support to ensure long-term success.
Investment Promotion
Global marketing campaigns to showcase Semicon City’s potential to the pharmaceutical sector.
Facilitation Services
End-to-end support in regulatory approvals, land acquisition, and operational setup.
Policy Clarity
Expert guidance on navigating government incentives, FDI policies, and compliance requirements.
Key Pharmaceutical Clusters Connected to Semicon City
Semicon City’s strategic location ensures seamless access to India’s leading pharmaceutical hubs:
- Ahmedabad: Bulk drug and formulation clusters.
- Hyderabad: Biologics and contract research centers.
- Mohali: Emerging hubs for biosimilars and vaccines.
- Kolkata: Captive and contract R&D units.
- Bengaluru: Advanced research and manufacturing facilities.
